NeuroPace (NPCE) News Today $10.49 +0.07 (+0.67%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period NeuroPace, Inc.: NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | finanznachrichten.deNeuroPace announces data from long-term post-approval study of RNS SystemApril 8, 2025 | markets.businessinsider.comNeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | globenewswire.comQ1 Earnings Forecast for NeuroPace Issued By Leerink PartnrsApril 8, 2025 | americanbankingnews.comQ1 Earnings Estimate for NeuroPace Issued By Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for NeuroPace in a research note issued to investors on Thursday, April 3rd. Leerink Partnrs analyst M. Kratky expects that the company will post earnings per shareApril 8, 2025 | marketbeat.comWells Fargo Remains a Buy on NeuroPace (NPCE)April 5, 2025 | markets.businessinsider.comNeuroPace (NPCE) Receives a Buy from Lake StreetApril 4, 2025 | markets.businessinsider.comNeuroPace, Inc. (NASDAQ:NPCE) Short Interest UpdateNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 308,300 shares, a growth of 25.5% from the February 28th total of 245,600 shares. Based on an average trading volume of 213,900 shares, the short-interest ratio is currently 1.4 days. Approximately 1.3% of the shares of the company are sold short.April 3, 2025 | marketbeat.comNeuroPace to terminate distribution relationship for Seeg productsApril 3, 2025 | markets.businessinsider.comNeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual MeetingApril 3, 2025 | globenewswire.comNeuroPace Announces Refocusing of Product PortfolioApril 2, 2025 | globenewswire.comNeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% - What's Next?NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% - Here's WhyMarch 30, 2025 | marketbeat.comNeuroPace to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | globenewswire.comNeuroPace at attractive entry point, remains best idea, says Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comNeuroPace’s SWOT analysis: stock poised for growth amid expanding marketMarch 14, 2025 | investing.comCantor Fitzgerald Predicts Higher Earnings for NeuroPaceNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of NeuroPace in a report issued on Wednesday, March 5th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of ($0.54) for the year, up fromMarch 8, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, Cantor Fitzgerald Analyst SaysCantor Fitzgerald lifted their target price on NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday.March 6, 2025 | marketbeat.comNeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Expectations By $0.07 EPSNeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.March 5, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | insidermonkey.comNeuroPace reports Q4 EPS (18c), consensus (22c)March 4, 2025 | markets.businessinsider.comNeuroPace sees FY25 revenue $92M-$96M, consensus $92.96MMarch 4, 2025 | markets.businessinsider.comNeuroPace, Inc. (NPCE) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comNeuroPace Inc.: Q4 Earnings SnapshotMarch 4, 2025 | finance.yahoo.comNeuroPace Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | globenewswire.comUPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comNeuroPace to Present at the Leerink Partners Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comLake Street Reaffirms Their Buy Rating on NeuroPace (NPCE)March 3, 2025 | markets.businessinsider.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Martha Morrell Sells 78,334 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) insider Martha Morrell sold 78,334 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the transaction, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.February 26, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $1,074,742.48 in StockFebruary 26, 2025 | insidertrades.comNeuroPace (NPCE) Expected to Announce Earnings on TuesdayNeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, March 4. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=668151)February 25, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 5,270,845 SharesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Ltd. Kck sold 5,270,845 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.February 21, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $49,545,943.00 in StockFebruary 21, 2025 | insidertrades.comNeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.February 20, 2025 | globenewswire.comNeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025February 19, 2025 | globenewswire.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesFebruary 18, 2025 | markets.businessinsider.comNeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesFebruary 18, 2025 | globenewswire.comNeuroPace to repurchase shares from major holderFebruary 14, 2025 | msn.comNeuroPace stock dips after pricing $65M share offeringFebruary 14, 2025 | msn.comNeuroPace announces pricing of $65M offering of common stockFebruary 14, 2025 | markets.businessinsider.comNeuroPace Announces Pricing of Public Offering of $65 Million of Common StockFebruary 14, 2025 | globenewswire.comNeuroPace plans $65 million stock offeringFebruary 13, 2025 | msn.comNeuroPace announces $65M common stock offeringFebruary 13, 2025 | markets.businessinsider.comNeuroPace Announces Proposed Public Offering of $65 Million of Common StockFebruary 13, 2025 | globenewswire.comNeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9thFebruary 3, 2025 | globenewswire.comNeuroPace FY2025 EPS Estimate Decreased by Cantor FitzgeraldNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for NeuroPace in a report issued on Wednesday, January 29th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.80) pJanuary 31, 2025 | marketbeat.comNeuroPace price target raised to $17 from $13 at Wells FargoJanuary 30, 2025 | markets.businessinsider.comWells Fargo & Company Forecasts Strong Price Appreciation for NeuroPace (NASDAQ:NPCE) StockWells Fargo & Company raised their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday.January 30, 2025 | marketbeat.comNeuroPace, Inc.: NeuroPace Issues 2025 Financial Guidance TargetsJanuary 30, 2025 | finanznachrichten.deLeerink Partnrs Comments on NeuroPace FY2029 EarningsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Tuesday, January 28th. Leerink Partnrs analyst M. Kratky expects that the company willJanuary 30, 2025 | marketbeat.comNeuroPace: Strategic Growth and Market Expansion Drive Positive OutlookJanuary 30, 2025 | markets.businessinsider.com Remove Ads Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.871.00▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼83▲NPCE Articles Average Week Remove Ads Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Warby Parker News Cadre News Kestra Medical Technologies News Tandem Diabetes Care News Paragon 28 News InMode News Liquidia News MiMedx Group News BioLife Solutions News Pulse Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe rotation into gold miners is on.They’re deeply undervalued gold developers with massive in-the-ground, proven resources - and now, fast-track ...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCFormer Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredThe biggest story CNBC isn't talking about (yet)This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NPCE Stock Free NPCE Stock Alerts